Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes
- 1Diabetes Center, Indiana Biosciences Research Institute, Indianapolis, IN, United States
- 2Department of Medicine, Endocrinology, Diabetes & Metabolism, Baylor College of Medicine, Houston, TX, United States
- 3Department of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, United States
- 4Melvin and Bren Simon Comprehensive Cancer Center, Experimental and Developmental Therapeutics, School of Medicine, Indiana University, Indianapolis, IN, United States
- 5Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, United States
- 6Herman B Wells Center for Pediatric Research and Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States
- 7School of Medicine, Indiana University Bloomington, Bloomington, IN, United States
- 8Diabetes Center, University of California San Francisco, San Francisco, CA, United States
- 9Department of Surgery, University of California San Francisco, San Francisco, CA, United States
- 10Gladstone Institute of Genomic Immunology, University of California San Francisco, San Francisco, CA, United States
- 11Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, United States
- 12Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, United States
A corrigendum on
Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes
by Obarorakpor N, Patel D, Boyarov R, Amarsaikhan N, Cepeda JR, Eastes D, Robertson S, Johnson T, Yang K, Tang Q and Zhang L (2023) Front. Immunol. 14:1207108. doi: 10.3389/fimmu.2023.1207108
In the published article, there was an error in the Funding statement. Grant “JDRF 2-SRA-2018-648-S-B” grant was missing in the statement. The correct Funding statement appears below.
Funding
This study was supported by grants from NIH R03AI139811-01A1, DoD W81XWH2210087, JDRF 2-SRA-2018-648-S-B, and a Pilot and Feasibility Award from the CDMD NIH/NIDDK Grant Number P30 DK097512 (to LZ).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Type 1 diabetes, regulatory T cell, chimeric antigen receptor, antigen specific immunotherapy, MHC II/Insulin complex, monoclonal antibody
Citation: Obarorakpor N, Patel D, Boyarov R, Amarsaikhan N, Cepeda JR, Eastes D, Robertson S, Johnson T, Yang K, Tang Q and Zhang L (2024) Corrigendum: Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes. Front. Immunol. 15:1391518. doi: 10.3389/fimmu.2024.1391518
Received: 26 February 2024; Accepted: 01 March 2024;
Published: 07 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Obarorakpor, Patel, Boyarov, Amarsaikhan, Cepeda, Eastes, Robertson, Johnson, Yang, Tang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Li Zhang, TFpoYW5nQEluZGlhbmFiaW9zY2llbmNlcy5vcmc=